Aktuelle Neurologie 2016; 43(07): 428-434
DOI: 10.1055/s-0042-112022
© Georg Thieme Verlag KG Stuttgart · New York

Medikamentöse Therapie des Parkinson-Syndroms: Selbsteinschätzung der Parkinson-Patienten in einer Querschnittserhebung

Drug Treatment of Parkinson‘s Disease: Self-Assessment of Patients in a Cross-Sectional Survey
W. H. Jost
1   Zentrum für Bewegungsstörungen, Parkinson-Klinik Ortenau
K. Engemann
2   Medizinische Abteilung, Zambon GmbH, Berlin
› Author Affiliations
Further Information

Publication History

Publication Date:
18 August 2016 (online)


In Deutschland fehlen aktuelle Daten zur Behandlungssituation von Parkinson-Patienten. Entsprechend wurde deshalb eine Querschnittserhebung an 4 485 Patienten sowie den behandelnden niedergelassenen Neurologen durchgeführt. Die Patienten wurden zum Krankheitsverlauf, der Behandlungshistorie und aktuellen Behandlung sowie ihrer Therapiezufriedenheit befragt.

Der Zeitraum zwischen Diagnosestellung und der erstmaligen Verordnung von Parkinson-Medikamenten war bei 68,9% der Patienten unter 3 Monate, bei 15,6% zwischen 3 und 6 Monaten, bei 7,1% bis zu einem Jahr, bei 3,3% bis 2 Jahre und mehr als 2 Jahre bei 3,1%. Von den Patienten schätzten sich 9,7% im Anfangsstadium der Erkrankung, 44,3% im mittleren Stadium und 41,3% im fortgeschrittenen Stadium ein. Den Behandlungserfolg ihrer Parkinson-Therapie beurteilten 4,9% als sehr gut, 22,6% als gut, 43,4% als zufriedenstellend, 17,6% als nicht zufriedenstellend, 5,4% als unbefriedigend und 2,1% als schlecht (4,1% keine Angabe). Den Behandlungserfolg ihrer Therapie machten 51,3% der Patienten an den motorischen Symptomen, 6,5% an nicht-motorischen Symptomen, 23,4% an der Wahrnehmungsfähigkeit, 57,0% an der Lebensqualität und 21,5% an der Beeinträchtigung durch die Medikation fest. In Hinblick auf die aktuelle Therapie fühlten sich 41,8% durch die Einnahmehäufigkeit gestört, 3,2% durch die Art der Anwendung, 12,3% durch die Mehrfachmedikation, 27,7% durch eine unzureichende Wirksamkeit und 41,29% durch Nebenwirkungen (Mehrfachnennungen möglich). Insgesamt bewerteten nur 27,5% der Patienten ihre aktuelle Parkinson-Therapie als sehr gut oder gut, die meisten jedoch diese nur als zufriedenstellend oder sogar als nicht zufriedenstellend. Diese Aussage stand im deutlichen Kontrast zur wesentlich positiveren globalen Einschätzung der behandelnden Ärzte.

Zusammenfassend berichten die Patienten Defizite in der medikamentösen Versorgung. Es besteht ein deutlicher Handlungsbedarf in Bezug auf die Informationsweitergabe an Patienten (u. a. Erklärung von Nebenwirkungen bzw. Differenzierung von Symptomen der Parkinson-Erkrankung) und für eine Umstellung der Medikationsschemata auf andere Präparate oder Kombinationen.


In Germany, data on the current treatment situation of patients with Parkinson‘s disease are lacking. Therefore, a cross-sectional survey of 4485 patients and neurologists treating them was performed. Patients were questioned on disease progression, treatment history, current treatment, and satisfaction with treatment. The time between diagnosis and initial prescription of drugs to treat the disease varied between 3 months and 2 years. Patient assessment of their disease stage was also varied considerably. Improvement was reported in motor symptoms (51.3%), in non-motor symptoms (6.5%), in perception (23.4%), quality-of-life (57.0%) and reduction in medication-associated impairment (21.5%). With regard to the current therapy, 41.8% felt disturbed by frequency of administration, 3.2% by the type of application, 12.3% by multiple medication, 27.7% due to insufficient efficacy and 41.29% by side effects (multiple answers possible). Overall, only 27.5% of patients rated their current Parkinson’s disease therapy as good or very good, but most of them reported therapy as being satisfactory or even unsatisfactory. This statement was in marked contrast to the much more positive global assessment made by physicians treating these patients. Patients report deficits in medical care with drugs. There is a clear need for action in relation to providing information to patients (explanation of side effects or differentiation of symptoms) and for a change of medication regimens to other compounds or combinations.

Ergänzendes Material

  • Literatur

  • 1 Riedel O, Bitters D, Amann U et al. Estimating the prevalence of Parkinson’s disease (PD) and proportions of patients with associated dementia and depression among the older adults based on secondary claims data. Int J Geriatr Psychiatry 2016; (online first)
  • 2 Dorsey ER, Constantinescu R, Thompson JP et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007; 68: 384-386
  • 3 Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8: 464-474
  • 4 Rizzo G, Copetti M, Arcuti S et al. Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis. Neurology 2016; 86: 566-576
  • 5 Jimenez-Shahed J. A review of current and novel levodopa formulations for the treatment of Parkinson’s disease. Ther Deliv 2016; 7: 179-191
  • 6 Ceravolo R, Rossi C, Del Prete E et al. A review of adverse events linked to dopamine agonists in the treatment of Parkinson’s disease. Expert Opin Drug Saf 2016; 15: 181-198
  • 7 Marsala SZ, Gioulis M, Ceravolo R et al. A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice. Clin Neuropharmacol 2012; 35: 185-190
  • 8 Rascol O, Perez-Lloret S, Ferreira JJ. New treatments for levodopa-induced motor complications. Mov Disord 2015; 30: 1451-1460
  • 9 Faulkner MA. Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson’s disease. Expert Opin Drug Saf 2014; 13: 1055-1069
  • 10 Perez-Lloret S, Rascol O. The safety and efficacy of safinamide mesylate for the treatment of Parkinson’s disease. Expert Rev Neurother 2016; 1-14
  • 11 Fabbri M, Rosa MM, Abreu D et al. Clinical pharmacology review of safinamide for the treatment of Parkinson’s disease. Neurodegener Dis Manag 2015; 5: 481-496
  • 12 Uebelacker LA, Epstein-Lubow G, Lewis T et al. A survey of Parkinson’s disease patients: most bothersome symptoms and coping preferences. J Parkinsons Dis 2014; 4: 717-723
  • 13 Buetow S, Giddings LS, Williams L et al. Perceived unmet needs for health care among Parkinson’s Society of New Zealand members with Parkinson’s disease. Parkinsonism Relat Disord 2008; 14: 495-500
  • 14 Dorsey ER, Voss TS, Shprecher DR et al. A U.S. survey of patients with Parkinson’s disease: satisfaction with medical care and support groups. Mov Disord 2010; 25: 2128-2135
  • 15 Bloem BR, Stocchi F. Move for change part I: a European survey evaluating the impact of the EPDA Charter for People with Parkinson’s disease. Eur J Neurol 2012; 19: 402-410
  • 16 Bloem BR, Stocchi F. Move for Change Part III: a European survey evaluating the impact of the EPDA Charter for People with Parkinson’s Disease. Eur J Neurol 2015; 22: 133-141 e8-e9
  • 17 Delgado-Rodriguez M, Llorca J. Bias. J Epidemiol Community Health 2004; 58: 635-641
  • 18 Eggert K, Oertel W, Reichmann HH Deutsche Gesellschaft für Neurologie (DGN). Parkinson-Syndrome – Diagnostik und Therapie (S2-Leitlinie), Stand September 2012. AWMF-Registernummer: 030/010
  • 19 Eggert K, Larisch A, Dodel R et al. Awareness and knowledge of the clinical practice guideline on Parkinson’s disease among German neurologists. Eur Neurol 2009; 61: 216-222
  • 20 Larisch A, Oertel WH, Eggert K. Attitudes and barriers to clinical practice guidelines in general and to the guideline on Parkinson’s disease. A National Survey of German neurologists in private practice. J Neurol 2009; 256: 1681-1688
  • 21 Jenner P. Wearing off, dyskinesia, and the use of continuous drug delivery in Parkinson’s disease. Neurol Clin 2013; 31: S17-S35
  • 22 Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Arch Neurol 1999; 56: 529-535
  • 23 Stocchi F, Rascol O, Kieburtz K et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010; 68: 18-27
  • 24 Storch A, Schneider CB, Wolz M et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 2013; 80: 800-809
  • 25 Schrag A, Dodel R, Spottke A et al. Rate of clinical progression in Parkinson’s disease. A prospective study. Movement Disorders 2007; 22: 938-945
  • 26 Csoti I, Jost WH, Reichmann H. Parkinson’s disease between internal medicine and neurology. J Neural Transm (Vienna) 2016; 123: 3-17
  • 27 Palacios N, Gao X, Schwarzschild M et al. Declining quality of life in Parkinson disease before and after diagnosis. J Parkinsons Dis 2012; 2: 153-160
  • 28 Muslimovic D, Post B, Speelman JD et al. Determinants of disability and quality of life in mild to moderate Parkinson disease. Neurology 2008; 70: 2241-2247
  • 29 Sethi KD. The impact of levodopa on quality of life in patients with Parkinson disease. Neurologist 2010; 16: 76-83
  • 30 Gellad WF, Grenard JL, Marcum ZA. A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. Am J Geriatr Pharmacother 2011; 9: 11-23
  • 31 Malek N, Grosset DG. Medication adherence in patients with Parkinson’s disease. CNS Drugs 2015; 29: 47-53
  • 32 Daley DJ, Myint PK, Gray RJ et al. Systematic review on factors associated with medication non-adherence in Parkinson’s disease. Parkinsonism Relat Disord 2012; 18: 1053-1061
  • 33 Chou KL. Adverse events from the treatment of Parkinson’s disease. Neurol Clin 2008; 26: S65-S83 vi
  • 34 Diaz NL, Waters CH. Current strategies in the treatment of Parkinson’s disease and a personalized approach to management. Expert Rev Neurother 2009; 9: 1781-1789